3′-Phosphoadenosine 5′-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents

Standard treatment for advanced non-small cell lung cancer (NSCLC) with no known driver mutation is platinum-based chemotherapy, which has a response rate of only 30–33%. Through an siRNA screen, 3′-phosphoadenosine 5′-phosphosulfate (PAPS) synthase 1 (PAPSS1), an enzyme that synthesizes the biologi...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncotarget
मुख्य लेखकों: Leung, Ada W. Y., Dragowska, Wieslawa H., Ricaurte, Daniel, Kwok, Brian, Mathew, Veena, Roosendaal, Jeroen, Ahluwalia, Amith, Warburton, Corinna, Laskin, Janessa J., Stirling, Peter C., Qadir, Mohammed A., Bally, Marcel B.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Impact Journals LLC 2015
विषय:
Research Paper
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4627299/
https://ncbi.nlm.nih.gov/pubmed/26220590
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन